Literature DB >> 31612068

Frequency of hematologic malignancies in the population of Arica, Chile.

Gloria Baeza Pérez1, Gloria M Calaf2,3, María Teresa Montalvo Villalba4, Katherine Salgado Prieto4, Fresia Caba Burgos5.   

Abstract

Hematologic diseases are a heterogeneous group of malignancies that affect people worldwide such as leukemia, lymphoma and multiple myelomas. The aim of this study was to characterize the frequency of hematological diseases in the population of Arica, Chile (18°S, 70°W), between 2011 and 2014. A total of 108 cases of hematologic malignancies were registered at Dr. Juan Noé Crevani Regional Hospital in this period; 40 male and 52 female cases were included in this retrospective and descriptive analysis. The overall median age at diagnosis for hematological malignancies was 59 years (range, 17 to 96 years). The results indicated that the frequency of hematological diseases such as non-Hodgkin lymphoma and leukemia was not associated with sex, ethnicity and type of disease. However, in 2012 there was an increased number of cases of Hodgkin lymphoma compared with any other year in the study, whereas the number of multiple myeloma cases decreased between 2011 and 2014. No significant differences were observed among different types of disease, nor among the types of leukemia. However, when intervals of age were considered, it was revealed that patients >75 years had the highest incidence of hematological malignancies, mainly multiple myeloma, compared with other age groups. However, young adults were more commonly diagnosed with Hodgkin lymphoma than other disease types. A non-significant difference was observed in leukemia between 2011 and 2014 when sex was taken into consideration, in which the incidence rate was higher in females compared with males. Hodgkin lymphoma was most commonly at stage II and non-Hodgkin lymphoma was most commonly at stage IV. No significant differences were observed between the nodal and extranodal type, mixed cellularity and nodular sclerosis or in the morphology of non-Hodgkin lymphoma cell type. Overall, there was a decrease in the frequency of hematological malignancies between 2011 and 2014, but no significant differences were observed in males or females. This study provided for the first time the pattern and distribution of hematological diseases in Arica, Chile.
Copyright © 2019, Spandidos Publications.

Entities:  

Keywords:  Hodgkin lymphoma; frequency; hematologic diseases; leukemia; multiple myeloma; non-Hodgkin lymphoma

Year:  2019        PMID: 31612068      PMCID: PMC6781717          DOI: 10.3892/ol.2019.10858

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  23 in total

1.  [Haematological malignancies: incidence in Basse-Normandie, France, for 1997-2004].

Authors:  X Troussard; V Duchenet; E Cornet; D Mouchel; M Malet; A Collignon
Journal:  Rev Epidemiol Sante Publique       Date:  2009-04-17       Impact factor: 1.019

Review 2.  Causes of oncogenic chromosomal translocation.

Authors:  Peter D Aplan
Journal:  Trends Genet       Date:  2005-10-28       Impact factor: 11.639

Review 3.  The 2016 revision of the World Health Organization classification of lymphoid neoplasms.

Authors:  Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe
Journal:  Blood       Date:  2016-03-15       Impact factor: 22.113

Review 4.  Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology.

Authors:  Antonia M S Müller; Gabriele Ihorst; Roland Mertelsmann; Monika Engelhardt
Journal:  Ann Hematol       Date:  2004-10-09       Impact factor: 3.673

5.  MicroRNA profiling can classify acute leukemias of ambiguous lineage as either acute myeloid leukemia or acute lymphoid leukemia.

Authors:  David C de Leeuw; Willemijn van den Ancker; Fedor Denkers; Renée X de Menezes; Theresia M Westers; Gert J Ossenkoppele; Arjan A van de Loosdrecht; Linda Smit
Journal:  Clin Cancer Res       Date:  2013-02-26       Impact factor: 12.531

6.  Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1976-08       Impact factor: 6.998

7.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

8.  Distribution and features of hematological malignancies in Eastern Morocco: a retrospective multicenter study over 5 years.

Authors:  Mounia Elidrissi Errahhali; Manal Elidrissi Errahhali; Redouane Boulouiz; Meryem Ouarzane; Mohammed Bellaoui
Journal:  BMC Cancer       Date:  2016-02-25       Impact factor: 4.430

9.  Alcohol drinking, tobacco smoking and subtypes of haematological malignancy in the UK Million Women Study.

Authors:  M E Kroll; F Murphy; K Pirie; G K Reeves; J Green; V Beral
Journal:  Br J Cancer       Date:  2012-08-09       Impact factor: 7.640

Review 10.  Risk factors for acute leukemia in children: a review.

Authors:  Martin Belson; Beverely Kingsley; Adrianne Holmes
Journal:  Environ Health Perspect       Date:  2007-01       Impact factor: 9.031

View more
  2 in total

1.  Hematological malignancies in the Northwest Ethiopia.

Authors:  Bamlaku Enawgaw; Melak Aynalem; Mulugeta Melku; Fikir Asrie; Molla Abebe; Aregawi Yalew; Tiruzer Bekele; Nebiyu Mesfin; Mulugeta Ayalew; Elias Shiferaw
Journal:  PLoS One       Date:  2021-12-01       Impact factor: 3.240

Review 2.  Current understanding of epigenetics mechanism as a novel target in reducing cancer stem cells resistance.

Authors:  Saeedeh Keyvani-Ghamsari; Khatereh Khorsandi; Azhar Rasul; Muhammad Khatir Zaman
Journal:  Clin Epigenetics       Date:  2021-05-29       Impact factor: 6.551

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.